November 16, 2022
SeQure Dx emerges from stealth mode to fulfill the promise of on-target gene editing therapies for biopharma partners, physicians, and patients
Building on Dr. J. Keith Joung’s ONE-seq platform, SeQure Dx has developed a portfolio of assays and data solutions to find, assess, and manage off-target risks from discovery to clinical development to patient impact.
August 03, 2021
SeQure Dx Announces $17.5M Series A Funding
Patented technology addresses emerging need for personalized diagnostics that assess the risks of gene-editing therapies